Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish
  • Turkish

Breadcrumb

  1. Home
  2. The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
  3. Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
  3. Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment
Gynecology

Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment

Drug
Urology

A vicious circle. Vaginal tract infections such as vulvovaginal candidiasis often appear after antibiotic therapy, and sometimes following the administration of antibiotics commonly used to treat those same infections. The situation is no better for urinary tract infections: antibiotics typically used to treat them have become a risk factor for their occurrence.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Author

Dr. Jean-Marc Bohbot
Created 25 August 2021
Updated 29 August 2024

Historically, until recent scientific work, urine was regarded as sterile. Compared to other microbiota, this ecosystem has low biomass.1 While a consensus regarding the precise composition has yet to be reached, around 100 species have been identified from 4 principal phyla (Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes).2 And though the role of the urinary microbiota is currently a matter of debate, it is well understood that diminished diversity seems to be a risk factor for urinary tract infections.

10 to 30 %

After antibiotic treatment, 10 to 30 % of women develop vulvovaginal candidiasis5

Yet, the vaginal microbiota gains on the other hand from having low diversity and being largely dominated by lactobacilli.3 Despite considerable variability among women, 5 community state types (CST) have been described in the vaginal flora: 4 dominated by one or several species of the Lactobacillus genus (L. crispatus, L. gasseri, L. iners or L. jensenii) and one polymicrobial.4 In both cases, dysbiosis following antibiotic treatment may increase the risk of infection.5

A spectrum of fungus at each antibiotic treatment 

This is what many women being treated with antibiotics dread: developing post-antibiotic vulvovaginal candidiasis. This anxiety is more than justified: antibacterial therapy, whether systemic or applied locally to the vagina, is thought to be one of the main factors leading to vulvovaginal candidiasis.5 This infection may be associated with vaginal microbiota disruption together with Candida yeast proliferation (C. albicans in the majority of cases ; Figure 3). The most common clinical signs of this infection are vulvar pruritus, a burning sensation accompanied by vaginal pain or irritation that may lead to dyspareunia or dysuria.6

 

FIGURE 3. Yeast proliferation induced by antibiotics exposure

Image

Urinary tract infections: what to prescribe?

According to the 2017 update of the German clinical guidelines on managing uncomplicated urinary tract infections in adult patients:9

  • “For the treatment of acute uncomplicated cystitis (AUC), fosfomycin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, and trimethoprim (depending on the local rate of resistance) are all equally recommended. Cotrimoxazole, fluoroquinolones, and cephalosporins are not recommended as antibiotics of first choice, due to concerns over the possibility of an unfavorable impact on the microbiome.

  • For AUC with mild to moderate symptoms, instead of antibiotics, symptomatic treatment alone may be considered depending on the patient’s preference after discussing possible adverse events and outcomes.

  • Primarily non-antibiotic options are recommended for prophylaxis of recurrent urinary tract infections.”

The vicious circle of bacterial vaginosis

Though the etiology of bacterial vaginosis (BV), the main form of vaginal infection, remains unclear, it is believed that antibiotic-induced dysbiosis could be partly responsible for its development: dominant lactobacilli are supplanted by polymicrobial flora derived from numerous bacterial genera (Gardnerella, Atopobium, Prevotella, etc.). A vicious circle could be initiated: though antibiotics can be used to treat BV, they are also, alongside sexual history, vaginal douching, contraceptive use, age, stage in the menstrual cycle, tobacco use, etc., among the numerous risk factors associated with this type of infection.7

Urinary microbiota: a textbook case of antibiotic resistance 

Urinary tract infections (UTI) affect millions of men (a 3% annual incidence rate in the US) and women (10%) every year.8 Recurrent UTIs contribute greatly to this incidence: notwithstanding their receiving appropriate antibiotic therapy, more than 30% of women will experience a subsequent infection within the following 12 months.8 UTIs are becoming increasingly difficult to treat because of the rapid spread of drug resistance among Gram-Negative organisms, notably UPEC (uropathogenic Escherichia coli) which cause approximately 80% of UTIs.8

Paradoxically, broadspectrum antibiotics used to treat both community acquired and hospital-associated UTIs have become a risk factor for their occurrence.8 Mechanisms involving both gut and vaginal microbiota are suspected: in the gut, the ultimate reservoir for UPEC, antibiotic exposure increases inflammation and promotes the proliferation of E. coli; in the vagina, they diminish colonization by Lactobacillus species that suppress vaginal UPEC invasion and subsequent bacterial ascension from the vagina into the urinary tract. This is the reason why, experts nowadays recommend that they should be used with caution and that microbiota-sparing treatments should be developed.8

Expert opinion 

Urinary tract infections are closely linked to imbalances in any one of three microbiota: the urinary microbiota, since urine is not sterile; the vaginal microbiota, with which the urinary microbiota shares many similarities; and the gut microbiota, from where the pathogens involved in urinary tract infections originate (e.g. E. coli, which passes from the anus to the vulvar vestibule and then to the bladder).

Dr. JEAN-MARC BOHBOT, MD, PhD. Andrologist and Infectious Diseases Specialist, Institut Alfred Fournier, Paris (France)

Clinical case

by Dr. Jean-Marc Bohbot, MD, PhD

  • 18-year-old Solène consults for recurrent vulvo-vaginal candidiasis. For about 3 months, she suffers from recurrent candidiasis (2 episodes per month) with abundant white leucorrhea and intense vulvo-vaginal pruritus. These episodes have a very negative impact on her daily life, not to mention her sex life.

  • A vaginal sample confirmed the presence of Candida albicans with an intermediate vaginal microbiota (Nugent score 6). Solène has a regular partner who experiences no symptoms. She is not diabetic. The candidiasis appeared a few weeks after starting a daily antibiotic treatment (cyclines) for acne. These antibiotics promote vaginal dysbiosis and facilitate the development of fungi.

  • After consultation with the dermatologist, oral cyclines were replaced by a local treatment; the candidiasis disappeared within 2 weeks.

In cases of acne, the use of antibiotics should be limited or should be accompanied by probiotic cures to preserve the balance of the vaginal microbiota.

Sources

1 Neugent ML, Hulyalkar NV, Nguyen VH, et al. Advances in Understanding the Human Urinary Microbiome and Its Potential Role in Urinary Tract Infection. mBio. 2020 Apr 28;11(2):e00218-20.

2 Morand A, Cornu F, Dufour JC, et al. Human Bacterial Repertoire of the Urinary Tract: a Potential Paradigm Shift. J Clin Microbiol. 2019 Feb 27;57(3). pii: e00675-18.

3 Gupta S, Kakkar V, Bhushan I. et al. Crosstalk between Vaginal Microbiome and Female Health: A review. Microb Pathog. 2019 Aug 23;136:103696.

4 Greenbaum S, Greenbaum G, Moran-Gilad J, et al. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gynecol. 2019;220(4):324-335.

5 Shukla A, Sobel JD. Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. Curr Infect Dis Rep. 2019 Nov 9;21(11):44.

6 Gonçalves B, Ferreira C, Alves CT, et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016 Nov;42(6):905-27.

7 Coudray MS, Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2019 Dec 24;245:143-148.

8 Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18(4):211-226.

9 Kranz J, Schmidt S, Lebert C, et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278.

Old sources

 

 

Tags
Otitis Probiotics AAD Microbiome Flora

    See also

    Actu PRO : Maladie de parkinson : les antibiotiques, et le microbiote, impliqués Role of antibiotics and microbiota in parkinson's disease
    Actu PRO : Microbiote vaginal et prédisposition a la candidose Vaginal microbiota and predisposition to candidiasis
    Focus
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    • Introduction
      • The Janus face of Antibiotics: Life Savers and Microbiota Disruptors
    • Gut
      • From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis
    • Urogenital
      • Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment
    • Cutaneous
      • Antibiotics, a double-edged sword when managing skin disease
    • ENT
      • Ears, Nose and Throat microbiota: when antibiotics challenge our first line of defense
    • Lung
      • Antibiotic resistance: the lung microbiota pays a heavy price
    • Conclusion
      • What to take away?
    Created 25 August 2021
    Updated 29 August 2024

    About this article

    To know more about this topic.

    Main topic

    Drug

    Medical practice

    Urology

    Content type

    Dossier detail

    Author

    Dr. Jean-Marc Bohbot
    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis
    Antibiotics, a double-edged sword when managing skin disease
    Focus

    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters

    Introduction

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    Gut

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Urogenital

    Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment

    Cutaneous

    Antibiotics, a double-edged sword when managing skin disease

    ENT

    Ears, Nose and Throat microbiota: when antibiotics challenge our first line of defense

    Lung

    Antibiotic resistance: the lung microbiota pays a heavy price

    Conclusion

    What to take away?
    Gynecology
    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article
    02.04.2025

    A type of vaginal dysbiosis for each type of infertility?

    Read the article
    13.02.2025

    How do I deal with menopause?

    Read the article
    13.02.2025

    “I'm 45, why do I have all these symptoms now (hot flashes, insomnia, dryness, swollen belly)? Is it menopause?”

    Read the article
    13.02.2025

    Will having too much sex affect my pH, or give me vaginitis or thrush? Or will it give me a STI?

    Read the article
    13.02.2025

    "Help, I don't want to have sex anymore: I'm too tired, stressed, I don't feel sexy, what is wrong with me?"

    Read the article
    13.02.2025

    Why is it itching down there?

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish
    • Turkish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo